Phillip P. Chan, MD, PhD | Chief Executive Officer and President


Dr. Phillip Chan is the CEO and President of CytoSorbents Corporation. Prior to CytoSorbents, Dr. Chan led healthcare and life science investments as Partner for the $80M NJTC Venture Fund, one of the top performing and largest early stage investors in the greater New York region.  He was responsible for numerous investments in therapeutics, medical devices and diagnostics. Dr. Chan also co-founded Andrew Technologies, a venture-backed medical device company commercializing its FDA approved HydraSolve™ advanced lipoplasty system in the U.S. Dr. Chan received Board-certification in internal medicine, having completed his residency at Harvard Medical School at the Beth Israel Deaconess Medical Center. Dr. Chan received his MD/PhD from Yale University School of Medicine and his BS in cell and molecular biology from Cornell University.  In 2012, Dr. Chan was named an Ernst & Young New Jersey Entrepreneur-of-the-Year finalist.

Vincent Capponi, MS | Chief Operating Officer

Mr. Capponi has more than 20 years of management experience in medical device, pharmaceutical and imaging equipment at companies including Upjohn, Sims Deltec and Sabratek. Mr. Capponi joined CytoSorbents Inc. as our VP of Operations in 2002 until his promotion to Chief Operating Officer in 2005. Prior to joining CytoSorbents, he held several senior management positions at Sabratek and its diagnostics division GDS. Mr. Capponi was interim president of GDS diagnostics in 2001, and from 2000 to 2001 he was responsible for the integration of the Baxter-Sabratek acquisition. From 1998 to 2000 Mr. Capponi was Senior VP and COO for Sabratek and VP Operations from 1996 to 1998. Mr. Capponi has extensive experience in process scale-up and high volume medical disposables production. He received his MS in Chemistry and his BS in Chemistry and Microbiology from Bowling Green State University.

Kathleen Bloch, MBA, CPA | Chief Financial Officer

Ms. Bloch has more than 20 years of executive financial experience at both public and private companies. From 2008 to 2010, she served as the Chief Operating Officer of PC Group, Inc., where she was hired as CFO in 2007. Prior to this, Ms. Bloch managed the day-to-day operations for The Silverman Group, a real estate and investment company. For ten years prior she was employed by Silver Line Building Products Corporation, a leading privately-held manufacturer of vinyl windows. She served as CFO from 1999 until 2006 when the company was acquired by Andersen Corporation, a leading manufacturer of windows. She holds a Master of Business Administration degree and a Bachelor of Science Accounting degree from LaSalle University.

Eric Mortensen, M.D., Ph.D. | Chief Medical Officer

Dr. Mortensen has more than 20 years of clinical trial experience most recently as Vice President & Therapeutic Area Clinical Head for Inflammation and Immunology at Pfizer from 2014 to 2016, Dr. Mortensen led the company’s global, late-stage development organization for programs in inflammatory diseases including studies for Enbrel® and Xeljanz®. As the Clinical Inflammation Development Strategy Lead and co-chair for Inflammation’s Therapeutic Area Strategy Team (TAST), he ensured an integrated approach to the development of medicines across the different indications within Inflammation and Immunology. Dr. Mortensen previously held positions of increasing responsibility as the Vice President, Global Medicine Development Group Global Lead for Xeljanz and Assistant Vice President and Global Therapeutic Area Director for Enbrel.  Previously, Dr. Mortensen was at GlaxoSmithKline and Merck. Dr. Mortensen received an A.B. in Biochemistry from Harvard College, an M.D. from the Harvard University and Massachusetts Institute of Technology Division of Health Sciences and Technology (HST), and a Ph.D. in Biophysics at the Harvard Graduate School of Arts and Sciences.  Dr. Mortensen completed an internship and residency in Internal Medicine at the Massachusetts General Hospital and a fellowship in Gastroenterology at the University of Michigan Medical Center, Ann Arbor.

Christian Steiner, MD | Vice President of Sales and Marketing

Dr. Steiner is a native German and English-speaking sales executive who manages all direct sales and marketing efforts of CytoSorb® in Germany and distributor relationships outside the European Union. Dr. Steiner joins CytoSorbents from Critical Care Competence, a critical-care focused outsourced sales and marketing company in Germany, where he was Managing Director. He previously served as the Director of Corporate Marketing for Pulsion Medical Systems AG, a publicly-traded German medical device company focused on non-invasive hemodynamic monitoring, where he was responsible for launching new products such as PiCCO®, establishing physician relationships, building market awareness, initiating clinical studies, and helping to grow sales to approximately €30 million. Prior to that, as Director of Global Marketing at Teraklin AG, he led the clinical introduction of MARS™, which at that time was a completely new blood purification technology being spun out of University of Rostock, Germany, that was eventually purchased by Gambro AB.

Christopher Cramer, MS, MBA | Vice President of Business Development

Mr. Cramer leads business development at CytoSorbents and has more than 15 years of business development and commercial experience in the medical device field. Most recently, he was Senior Director of New Venture Development at Johnson & Johnson (J&J). He helped to create and manage J&J’s portfolio of early stage ventures from inception to product launch, establishing new revenue streams for Johnson & Johnson. He was personally responsible for initiating and driving significant partnership deal flow, and has substantial experience in negotiating and establishing business development relationships across many commercial, non-profit, and government organizations. These deals encompassed a wide variety of structures, including distribution, promotion, co-development, licensing, merger and acquisitions, and equity investments. Prior to that, he was the Worldwide Strategic Marketing leader responsible for developing and executing branding and business development strategies for J&J’s minimally invasive weight-loss surgery division. Prior to J&J, he held multiple leadership positions at PwC Consulting and Parametric Technology Corporation. Chris earned his BS degree from Miami University and MBA and MS degrees from Carnegie Mellon University.